The oligo-acyl lysyl antimicrobial peptide C 12K- 2β 12 exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 378-390

  Makobongo, Morris O ^a   Gancz, Hanan ^a   Carpenter, Beth M ^a   McDaniel, Dennis P ^a   Merrell, D Scott ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 N PHENYLNAPHTHYLAMINE; BACTERIAL DNA; BACTERIAL PROTEIN; BACTERIAL RNA; NAPHTHALENE DERIVATIVE; PEPTIDE C12K 2BETA12; PEPTIDOMIMETIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL; BACTERIAL COLONIZATION; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BINDING ASSAY; CHANNEL GATING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOLYSIS; CYTOPLASM; DOSE RESPONSE; DRUG DNA BINDING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; ELECTRON MICROSCOPY; ENZYME INACTIVATION; GERBIL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IN VIVO STUDY; LYSIS; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

1-NAPHTHYLAMINE; ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BLOTTING, WESTERN; CELL MEMBRANE PERMEABILITY; DNA, BACTERIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUORESCENT DYES; GERBILLINAE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON; PEPTIDOMIMETICS; PROTEIN BINDING; RNA, BACTERIAL; STOMACH;

EID: 84455173021     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00689-11     Document Type: Article

References (89)

1. Abachin E, et al. 2002. Formation of D-alanyl-lipoteichoic acid is required for adhesion and virulence of Listeria monocytogenes. Mol. Microbiol. 43:1-14. (Pubitemid 34212186)
2. Armstrong JA, Wee SH, Goodwin CS, Wilson DH. 1987. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro - an ultrastructural study. J. Med. Microbiol. 24:343-350. (Pubitemid 18024299)
3. Boman HG, Agerberth B, Boman A. 1993. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect. Immun. 61:2978-2984. (Pubitemid 23182296)
4. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250. (Pubitemid 40298223)
5. Carpenter BM, et al. 2009. A single nucleotide change affects fur-dependent regulation of sodB in H. pylori. PLoS One 4:e5369.
6. Carpenter BM, et al. 2007. Expanding the Helicobacter pylori genetic toolbox: modification of an endogenous plasmid for use as a transcriptional reporter and complementation vector. Appl. Environ. Microbiol. 73:7506-7514.
7. Cederbrant G, Kahlmeter G, Schalen C, Kamme C. 1994. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J. Antimicrob. Chemother. 34:1025-1029.
8. Chey WD, Wong BC. 2007. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 102:1808-1825. (Pubitemid 47206706)
9. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. 1999. Helicobacter pylori virulence and genetic geography. Science 284: 1328-1333. (Pubitemid 29289653)
10. De Yang, et al. 2000. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192:1069-1074.
11. Diekema DI, Jones RN. 2000. Oxazolidinones: a review. Drugs 59:7-16. (Pubitemid 30150569)
12. Ellison RT, III, Giehl TJ, LaForce FM. 1988. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect. Immun. 56:2774-2781. (Pubitemid 18259927)
13. Epand RF, Sarig H, Mor A, Epand RM. 2009. Cell-wall interactions and the selective bacteriostatic activity of a miniature oligo-acyl-lysyl. Biophys. J. 97:2250-2257.
14. Epand RM, Vogel HJ. 1999. Diversity of antimicrobial peptides and their mechanisms of action. Biochim. Biophys. Acta 1462:11-28.
15. Felga GE, et al. 2008. Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. World J. Gastroenterol. 14: 6224-6227.
16. Fiese EF, Steffen SH. 1990. Comparison of the acid stability of azithromycin and erythromycin A. J. Antimicrob. Chemother. 25(Suppl. A): 39-47. (Pubitemid 20043949)
17. Figura N, et al. 2004. Inactivation of Helicobacter pylori cagA gene affects motility. Helicobacter 9:185-193. (Pubitemid 38724753)
18. Franco AT, et al. 2005. Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc. Natl. Acad. Sci. U. S. A. 102:10646-10651. (Pubitemid 41061608)
19. Friedrich CL, Rozek A, Patrzykat A, Hancock RE. 2001. Structure and mechanism of action of an indolicidin peptide derivative with improved activity against gram-positive bacteria. J. Biol. Chem. 276:24015-24022.
20. Gancz H, Censini S, Merrell DS. 2006. Iron and pH homeostasis intersect at the level of Fur regulation in the gastric pathogen Helicobacter pylori. Infect. Immun. 74:602-614. (Pubitemid 43023116)
21. Gisbert JP, et al. 2008. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment. Pharmacol. Ther. 27:346-354.
22. Graham DY, Shiotani A. 2008. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat. Clin. Pract. Gastroenterol. Hepatol. 5:321-331. (Pubitemid 351803603)
23. Graham JE, Peek RM, Jr, Krishna U, Cover TL. 2002. Global analysis of Helicobacter pylori gene expression in human gastric mucosa. Gastroenterology 123:1637-1648. (Pubitemid 35231663)
24. Guina T, Yi EC, Wang H, Hackett M, Miller SI. 2000. A PhoP-regulated outer membrane protease of Salmonella enterica serovar typhimurium promotes resistance to alpha-helical antimicrobial peptides. J. Bacteriol. 182:4077-4086. (Pubitemid 30436571)
25. Gumurdulu Y, et al. 2004. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J. Gastroenterol. 10:668-671. (Pubitemid 38351533)
26. Hancock RE, Wong PG. 1984. Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob. Agents Chemother. 26:48-52. (Pubitemid 14086723)
27. Hassan IJ, Stark RM, Greenman J, Millar MR. 1998. Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637. J. Antimicrob. Chemother. 42:661-663. (Pubitemid 28510627)
28. Heilborn JD, et al. 2003. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Investig. Dermatol. 120:379-389. (Pubitemid 36298423)
29. Hirschl AM, Rotter ML. 1996. Amoxicillin for the treatment of Helicobacter pylori infection. J. Gastroenterol. 31(Suppl. 9):44-47. (Pubitemid 27026297)
30. Hocquellet A, et al. 2010. Structure-activity relationship of human liverexpressed antimicrobial peptide 2. Peptides 31:58-66.
31. Hopkins RJ, Girardi LS, Turney EA. 1996. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 110:1244-1252. (Pubitemid 26113765)
32. Hsu CH, et al. 2005. Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Res. 33:4053-4064. (Pubitemid 41487266)
33. Jang S, et al. 2010. Epidemiological link between gastric disease and polymorphisms in VacA and CagA. J. Clin. Microbiol. 48:559-567.
34. Jenssen H, Hamill P, Hancock RE. 2006. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19:491-511. (Pubitemid 44137212)
35. Jin T, et al. 2004. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J. Immunol. 172:1169-1176. (Pubitemid 38113778)
36. Jones KR, Cha JH, Merrell DS. 2008. Who's winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori. Curr. Drug Ther. 3:190-203.
37. Khrapunov S, Cheng H, Hegde S, Blanchard J, Brenowitz M. 2008. Solution structure and refolding of the Mycobacterium tuberculosis penta-peptide repeat protein MfpA. J. Biol. Chem. 283:36290-36299.
38. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810. (Pubitemid 47332566)
39. Kumagai T, et al. 2001. Serum immunoglobulin G immune response to Helicobacter pylori antigens in Mongolian gerbils. J. Clin. Microbiol. 39:1283-1288. (Pubitemid 32275421)
40. Kurosaka K, Chen Q, Yarovinsky F, Oppenheim JJ, Yang D. 2005. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol. 174:6257-6265. (Pubitemid 40663818)
41. Lai Y, et al. 2010. Activation of TLR2 by a small molecule produced by Staphylococcus epidermidis increases antimicrobial defense against bacterial skin infections. J. Investig. Dermatol. 130:2211-2221.
42. Liu AY, et al. 2002. Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J. Investig. Dermatol. 118:275-281. (Pubitemid 34158481)
43. Livne L, et al. 2009. Design and characterization of a broad-spectrum bactericidal acyl-lysyl oligomer. Chem. Biol. 16:1250-1258.
44. Loh B, Grant C, Hancock RE. 1984. Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26:546-551. (Pubitemid 14018094)
45. 2-casein f(183-207) and effect on bacterial membranes and cell morphology. Biochim. Biophys. Acta 1778:2444-2449.
46. Lugtenberg B, Van Alphen L. 1983. Molecular architecture and functioning of the outer membrane of Escherichia coli and other gram-negative bacteria. Biochim. Biophys. Acta 737:51-115. (Pubitemid 13129059)
47. Makobongo MO, Kovachi T, Gancz H, Mor A, Merrell DS. 2009. In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori. Antimicrob. Agents Chemother. 53:4231-4239.
48. Marchese A, Schito GC. 2001. The oxazolidinones as a new family of antimicrobial agent. Clin. Microbiol. Infect. 7(Suppl. 4):66-74. (Pubitemid 34966109)
49. Matsuzaki K, Murase O, Fujii N, Miyajima K. 1995. Translocation of a channel-forming antimicrobial peptide, magainin 2, across lipid bilayers by forming a pore. Biochemistry 34:6521-6526.
50. McDaniel DP, Roberson RW. 2000. Microtubules are required for motility and positioning of vesicles and mitochondria in hyphal tip cells of Allomyces macrogynus. Fungal Genet. Biol. 31:233-244. (Pubitemid 32202699)
51. Miles S, et al. 2010. Detailed in vivo analysis of the role of Helicobacter pylori Fur in colonization and disease. Infect. Immun. 78:3073-3082.
52. Mukhtar TA, Koteva KP, Wright GD. 2005. Chimeric streptogramin-tyrocidine antibiotics that overcome streptogramin resistance. Chem. Biol. 12:229-235. (Pubitemid 40281330)
53. Mutschler H, Gebhardt M, Shoeman RL, Meinhart A. 2011. A novel mechanism of programmed cell death in bacteria by toxin-antitoxin systems corrupts peptidoglycan synthesis. PLoS Biol. 9:e1001033.
54. Nan YH, Bang JK, Shin SY. 2009. Design of novel indolicidin-derived antimicrobial peptides with enhanced cell specificity and potent antiinflammatory activity. Peptides 30:832-838.
55. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
56. Nordahl EA, et al. 2004. Activation of the complement system generates antibacterial peptides. Proc. Natl. Acad. Sci. U. S. A. 101:16879-16884. (Pubitemid 39601332)
57. Panthel K, et al. 2003. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect. Immun. 71:109-116. (Pubitemid 36026010)
58. Park CB, Kim HS, Kim SC. 1998. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 244:253-257. (Pubitemid 28419934)
59. Park CB, Yi KS, Matsuzaki K, Kim MS, Kim SC. 2000. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc. Natl. Acad. Sci. U. S. A. 97:8245- 8250.
60. Peschel A, et al. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J. Exp. Med. 193:1067-1076. (Pubitemid 32436200)
61. Powers JP, Hancock RE. 2003. The relationship between peptide structure and antibacterial activity. Peptides 24:1681-1691. (Pubitemid 38198075)
62. Poyart C, et al. 2003. Attenuated virulence of Streptococcus agalactiae deficient in D-alanyl-lipoteichoic acid is due to an increased susceptibility to defensins and phagocytic cells. Mol. Microbiol. 49:1615-1625. (Pubitemid 37153520)
63. Psakis G, et al. 2009. The sodium-dependent D-glucose transport protein of Helicobacter pylori. Mol. Microbiol. 71:391-403.
64. Radzishevsky I, Krugliak M, Ginsburg H, Mor A. 2007. Antiplasmodial activity of lauryl-lysine oligomers. Antimicrob. Agents Chemother. 51:1753-1759. (Pubitemid 46744155)
65. Radzishevsky IS, et al. 2008. Structure-activity relationships of antibacterial acyl-lysine oligomers. Chem. Biol. 15:354-362. (Pubitemid 351508428)
66. Radzishevsky IS, et al. 2007. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat. Biotechnol. 25:657-659. (Pubitemid 46897206)
67. Ramakrishnan K, Salinas RC. 2007. Peptic ulcer disease. Am. Fam. Physician 76:1005-1012.
68. Rotem S, et al. 2008. Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J. 22:2652-2661.
69. Salvatore M, et al. 2007. Alpha-defensin inhibits influenza virus replication by cell-mediated mechanism(s). J. Infect. Dis. 196:835-843. (Pubitemid 47378932)
70. Sarig H, Goldfeder Y, Rotem S, Mor A. 2011. Mechanisms mediating bactericidal properties and conditions that enhance the potency of a broad-spectrum oligo-acyl-lysyl. Antimicrob. Agents Chemother. 55:688-695.
71. Sarig H, et al. 2010. A miniature mimic of host defense peptides with systemic antibacterial efficacy. FASEB J. 24:1904-1913.
72. Sarig H, Rotem S, Ziserman L, Danino D, Mor A. 2008. Impact of self-assembly properties on antibacterial activity of short acyl-lysine oligomers. Antimicrob. Agents Chemother. 52:4308-4314.
73. Schibli DJ, Epand RF, Vogel HJ, Epand RM. 2002. Tryptophan-rich antimicrobial peptides: comparative properties and membrane interactions. Biochem. Cell Biol. 80:667-677. (Pubitemid 36124825)
74. Scott D, Weeks D, Melchers K, Sachs G. 1998. The life and death of Helicobacter pylori. Gut 43(Suppl. 1):S56-S60. (Pubitemid 28338114)
75. Shai Y. 1999. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1462:55-70.
76. Sieprawska-Lupa M, et al. 2004. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob. Agents Chemother. 48:4673-4679. (Pubitemid 39577671)
77. Silvestro L, Gupta K, Weiser JN, Axelsen PH. 1997. The concentration-dependent membrane activity of cecropin A. Biochemistry 36:11452-11460. (Pubitemid 27408628)
78. Spratt BG, Cromie KD. 1988. Penicillin-binding proteins of gram-negative bacteria. Rev. Infect. Dis. 10:699-711.
79. Thompson LJ, et al. 2003. Gene expression profiling of Helicobacter pylori reveals a growth-phase-dependent switch in virulence gene expression. Infect. Immun. 71:2643-2655. (Pubitemid 36519880)
80. Tjabringa GS, et al. 2003. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol. 171:6690-6696.
81. Ulvatne H, Haukland HH, Samuelsen O, Kramer M, Vorland LH. 2002. Proteases in Escherichia coli and Staphylococcus aureus confer reduced susceptibility to lactoferricin B. J. Antimicrob. Chemother. 50:461-467. (Pubitemid 35214784)
82. Ulvatne H, Samuelsen O, Haukland HH, Kramer M, Vorland LH. 2004. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol. Lett. 237:377-384. (Pubitemid 39091973)
83. Viejo-Diaz M, Andres MT, Fierro JF. 2005. Different anti-Candida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1. Antimicrob. Agents Chemother. 49:2583-2588. (Pubitemid 40917565)
84. Williams DH. 1996. The glycopeptide story-how to kill the deadly 'superbugs'. Nat. Prod. Rep. 13:469-477. (Pubitemid 27025187)
85. Wirth HP, Beins MH, Yang M, Tham KT, Blaser MJ. 1998. Experimental infection of Mongolian gerbils with wild-type and mutant Helicobacter pylori strains. Infect. Immun. 66:4856-4866. (Pubitemid 28453093)
86. Xie M, et al. 2010. Rostrocaudal analysis of corpus callosum demyelination and axon damage across disease stages refines diffusion tensor imaging correlations with pathological features. J. Neuropathol. Exp. Neurol. 69:704-716.
87. Yeaman MR, Yount NY. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55:27-55. (Pubitemid 36268398)
88. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. (Pubitemid 34100944)
89. Zhao H, Mattila JP, Holopainen JM, Kinnunen PK. 2001. Comparison of the membrane association of two antimicrobial peptides, magainin 2 and indolicidin. Biophys. J. 81:2979-2991. (Pubitemid 33020082)